Nikita V. Baclig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nikita V. Baclig has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Antonia Osuna-Garcia
UCLA Louise M. Darling Biomedical Library, Los Angeles, USA
2 shared publicationsEden R. Brauer
UCLA School of Nursing, Los Angeles, USA
2 shared publicationsPatricia A. Ganz
UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA, Los Angeles, USA
2 shared publicationsVivek Chotai
University of California Los Angeles, Los Angeles, USA
2 shared publicationsAileen T. MacAndrew
Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California
1 shared publicationAlexis LeVee
1 shared publication
Latest Publications
- Open Access
- 30 July 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study
Purpose: Older adults with early-stage breast cancer (EBC) receiving neo/adjuvant chemotherapy frequently discontinue treatment early. However, the incidence, risk factors, and survival implications of early discontinuation remain poorly understood. Methods: This is a post hoc analysis of 501 older adults (aged ≥65) with EBC treated with neo/adjuvant chemotherapy from the Hurria Older PatiEnts (HOPE) Study. Before chemotherapy, we collected sociodemographic, clinical, and geriatric assessment characteristics. The primary outcome was early discontinuation (yes/no), defined as not completing all planned chemotherapy. We used multivariable logistic regression with stepwise selection to identify pretreatment risk factors and the Kaplan-Meier method to evaluate the impact of discontinuation on survival. Results: Of 501 participants (median [range] age, 70 [65-86] years), 113 (23%) had early discontinuation. After multivariable analysis, ≥1 fall within 6 months (odds ratio [OR] = 2.06, 95% CI = 1.11 to 3.81, P = .02) and an activity of daily living score <85 (OR = 2.00, 95% CI = 1.26 to 3.18, P = .003) were identified as risk factors for early discontinuation. Participants with both risk factors were at highest risk (OR = 4.61, 95% CI = 2.18 to 9.79, P < .001). With a median follow-up of 4.3 years, early discontinuation was not associated with worse overall or breast cancer-specific survival but was associated with higher non-breast cancer-specific mortality (hazard ratio = 2.94, 95% CI = 1.22 to 7.07, P = .02). Conclusion: In this cohort of older adults with EBC, nearly one-quarter discontinued chemotherapy early. Early discontinuation was associated with increased non-cancer-related mortality but not cancer-related mortality, emphasizing the importance of identifying high-risk older adults and optimizing treatment delivery.
- 30 July 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Open AccessEarly discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study
Purpose: Older adults with early-stage breast cancer (EBC) receiving neo/adjuvant chemotherapy frequently discontinue treatment early. However, the incidence, risk factors, and survival implications of early discontinuation remain poorly understood. Methods: This is a post hoc analysis of 501 older adults (aged ≥65) with EBC treated with neo/adjuvant chemotherapy from the Hurria Older PatiEnts (HOPE) Study. Before chemotherapy, we collected sociodemographic, clinical, and geriatric assessment characteristics. The primary outcome was early discontinuation (yes/no), defined as not completing all planned chemotherapy. We used multivariable logistic regression with stepwise selection to identify pretreatment risk factors and the Kaplan-Meier method to evaluate the impact of discontinuation on survival. Results: Of 501 participants (median [range] age, 70 [65-86] years), 113 (23%) had early discontinuation. After multivariable analysis, ≥1 fall within 6 months (odds ratio [OR] = 2.06, 95% CI = 1.11 to 3.81, P = .02) and an activity of daily living score <85 (OR = 2.00, 95% CI = 1.26 to 3.18, P = .003) were identified as risk factors for early discontinuation. Participants with both risk factors were at highest risk (OR = 4.61, 95% CI = 2.18 to 9.79, P < .001). With a median follow-up of 4.3 years, early discontinuation was not associated with worse overall or breast cancer-specific survival but was associated with higher non-breast cancer-specific mortality (hazard ratio = 2.94, 95% CI = 1.22 to 7.07, P = .02). Conclusion: In this cohort of older adults with EBC, nearly one-quarter discontinued chemotherapy early. Early discontinuation was associated with increased non-cancer-related mortality but not cancer-related mortality, emphasizing the importance of identifying high-risk older adults and optimizing treatment delivery.
- Open Access
- 20 July 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (9) , 91-100
Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer
- 20 July 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (9) , 91-100
Open AccessIncidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer
- Open Access
- 18 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Oncofertility patterns after the overturn of Roe v Wade
The 2022 US Supreme Court decision Dobbs v Jackson Women’s Health Organization raised concerns about access to fertility care for patients with cancer, yet there is limited evidence of its real-world impact. We conducted a national survey of National Comprehensive Cancer Network member institutions to evaluate changes in fertility preservation access and utilization in the 24 months following Dobbs. Of 33 institutions surveyed, 24 (72.7%) responded. Most (83.3%) institutions reported that reproductive care remained a clinical priority, and 62.5% reported increased fertility preservation utilization. Nearly all respondents reported stable or expanded institutional resources and staffing to support oncofertility services. Institutions in less restrictive states appeared to absorb increased demand, however notable nonresponse from institutions in restrictive policy environments limited our findings. This study suggests relative resilience among academic cancer centers but highlights the need for further study to ensure equitable access to fertility preservation in the post-Dobbs era.
- 18 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Open AccessOncofertility patterns after the overturn of Roe v Wade
The 2022 US Supreme Court decision Dobbs v Jackson Women’s Health Organization raised concerns about access to fertility care for patients with cancer, yet there is limited evidence of its real-world impact. We conducted a national survey of National Comprehensive Cancer Network member institutions to evaluate changes in fertility preservation access and utilization in the 24 months following Dobbs. Of 33 institutions surveyed, 24 (72.7%) responded. Most (83.3%) institutions reported that reproductive care remained a clinical priority, and 62.5% reported increased fertility preservation utilization. Nearly all respondents reported stable or expanded institutional resources and staffing to support oncofertility services. Institutions in less restrictive states appeared to absorb increased demand, however notable nonresponse from institutions in restrictive policy environments limited our findings. This study suggests relative resilience among academic cancer centers but highlights the need for further study to ensure equitable access to fertility preservation in the post-Dobbs era.
- Open Access
- 14 June 2024
- Published by Springer Nature in Systematic Reviews
- Vol. 13 (1) , 1-8
The sequelae of hematopoietic stem cell transplantation in adolescents and young adults: protocol for a systematic review
Background: Hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for adolescents and young adults (ages 15–39) with hematologic malignancy. Given the significant developmental milestones usually achieved during this unique life stage, this population is especially vulnerable to the interruption caused by a cancer diagnosis and its treatment. HSCT is a particularly invasive form of cancer therapy with many negative physical, social, and psychological sequelae. The long-term impact of HSCT in adolescents and young adults with hematologic malignancies warrants a systematic investigation of its effects to best shape clinical care and health policy. Methods: This protocol for a systematic review will focus on the long-term physical, psychological, social, spiritual, and health behavior effects experienced by adolescents and young adults who undergo HSCT for hematologic malignancy. We have constructed a specific search strategy that queries these five domains, which will be applied to five databases—Embase, PubMed, Cochrane Trials and Reviews, PsychInfo, and CINAHL—to identify the key literature. Two independent reviewers will perform a title/abstract screen followed by a full-text screen using standard screening templates to ensure the inclusion of outcomes in the post-acute HSCT period. Risk of bias will be assessed using the University of Adelaide Joanna Briggs Institute Collaboration Critical Appraisal Tools. Data from included studies will be abstracted on study characteristics, study setting, sample characteristics, and outcomes. Given the broad scope of the research question, data synthesis will focus on qualitative methods in accordance with Institute of Medicine standards. Discussion: While adolescents and young adults undergoing hematopoietic stem cell transplantation for hematologic malignancy are understood to have a unique survivorship experience, the sequelae of this treatment approach in this population have not been previously aggregated. This systematic review intends to expand insight into the adolescent and young adult experiences with HSCT in order to inform age-appropriate survivorship care and deliver this life-saving intervention with the best possible outcomes. Systematic review registration: PROSPERO CRD42022361663
- 14 June 2024
- Published by Springer Nature in Systematic Reviews
- Vol. 13 (1) , 1-8
Open AccessThe sequelae of hematopoietic stem cell transplantation in adolescents and young adults: protocol for a systematic review
Background: Hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for adolescents and young adults (ages 15–39) with hematologic malignancy. Given the significant developmental milestones usually achieved during this unique life stage, this population is especially vulnerable to the interruption caused by a cancer diagnosis and its treatment. HSCT is a particularly invasive form of cancer therapy with many negative physical, social, and psychological sequelae. The long-term impact of HSCT in adolescents and young adults with hematologic malignancies warrants a systematic investigation of its effects to best shape clinical care and health policy. Methods: This protocol for a systematic review will focus on the long-term physical, psychological, social, spiritual, and health behavior effects experienced by adolescents and young adults who undergo HSCT for hematologic malignancy. We have constructed a specific search strategy that queries these five domains, which will be applied to five databases—Embase, PubMed, Cochrane Trials and Reviews, PsychInfo, and CINAHL—to identify the key literature. Two independent reviewers will perform a title/abstract screen followed by a full-text screen using standard screening templates to ensure the inclusion of outcomes in the post-acute HSCT period. Risk of bias will be assessed using the University of Adelaide Joanna Briggs Institute Collaboration Critical Appraisal Tools. Data from included studies will be abstracted on study characteristics, study setting, sample characteristics, and outcomes. Given the broad scope of the research question, data synthesis will focus on qualitative methods in accordance with Institute of Medicine standards. Discussion: While adolescents and young adults undergoing hematopoietic stem cell transplantation for hematologic malignancy are understood to have a unique survivorship experience, the sequelae of this treatment approach in this population have not been previously aggregated. This systematic review intends to expand insight into the adolescent and young adult experiences with HSCT in order to inform age-appropriate survivorship care and deliver this life-saving intervention with the best possible outcomes. Systematic review registration: PROSPERO CRD42022361663
- Open Access
- 31 October 2023
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 7 (6)
Mental health and care utilization in survivors of adolescent and young adult cancer
Adolescent and young adult cancer survivors experience mental health challenges, yet little is known about the evolution of these difficulties. This study explored mental health symptoms and utilization among long-term adolescent and young adult cancer survivors. Using 30 432 respondents from the 2019 National Health Interview Survey, this study compared adults with a history of adolescent and young adult cancer (diagnosed when patients were between 15 and 39 years of age) to adults without adolescent and young adult cancer. Mental health symptom severity was measured using the Patient Health Questionnaire depression scale and 7-item Generalized Anxiety Disorder questionnaires. Care utilization constituted psychotherapy and mental health medication use. Inverse propensity score weights were used to balance demographics and combined with survey weights. Descriptive statistics, multivariable generalized linear models, and structural equation modeling with 2-sided tests were used for analysis. We compared 639 adolescent and young adult survivors with 29 793 controls. Survivors were, on average, 20.5 years (SE = 0.74) past their cancer diagnosis dates. After adjusting for survey and propensity score weights, adolescent and young adult survivors reported more severe depression (incidence rate ratio = 1.42, 95% confidence interval [CI] = 1.09 to 1.84, P < .01) and anxiety (incidence rate ratio = 1.85, 95% CI = 1.55 to 2.21, P < .001). They were more likely to use psychotherapy (odds ratio = 1.91, 95% CI = 1.16 to 3.17, P < .05) and mental health medications (odds ratio = 1.89, 95% CI = 1.15 to 3.11, P < .05). Time since diagnosis was negatively associated with symptoms and utilization. Structural equation modeling demonstrated mediation of utilization effect by symptom severity. Adolescent and young adult survivors experience worse mental health in late survivorship, despite small improvements over time. We highlight the importance of survivorship care that addresses the long-term mental health needs of these survivors.
- 31 October 2023
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 7 (6)
Open AccessMental health and care utilization in survivors of adolescent and young adult cancer
Adolescent and young adult cancer survivors experience mental health challenges, yet little is known about the evolution of these difficulties. This study explored mental health symptoms and utilization among long-term adolescent and young adult cancer survivors. Using 30 432 respondents from the 2019 National Health Interview Survey, this study compared adults with a history of adolescent and young adult cancer (diagnosed when patients were between 15 and 39 years of age) to adults without adolescent and young adult cancer. Mental health symptom severity was measured using the Patient Health Questionnaire depression scale and 7-item Generalized Anxiety Disorder questionnaires. Care utilization constituted psychotherapy and mental health medication use. Inverse propensity score weights were used to balance demographics and combined with survey weights. Descriptive statistics, multivariable generalized linear models, and structural equation modeling with 2-sided tests were used for analysis. We compared 639 adolescent and young adult survivors with 29 793 controls. Survivors were, on average, 20.5 years (SE = 0.74) past their cancer diagnosis dates. After adjusting for survey and propensity score weights, adolescent and young adult survivors reported more severe depression (incidence rate ratio = 1.42, 95% confidence interval [CI] = 1.09 to 1.84, P < .01) and anxiety (incidence rate ratio = 1.85, 95% CI = 1.55 to 2.21, P < .001). They were more likely to use psychotherapy (odds ratio = 1.91, 95% CI = 1.16 to 3.17, P < .05) and mental health medications (odds ratio = 1.89, 95% CI = 1.15 to 3.11, P < .05). Time since diagnosis was negatively associated with symptoms and utilization. Structural equation modeling demonstrated mediation of utilization effect by symptom severity. Adolescent and young adult survivors experience worse mental health in late survivorship, despite small improvements over time. We highlight the importance of survivorship care that addresses the long-term mental health needs of these survivors.
- Open Access
- 11 September 2023
- Published by Springer Nature in Research Square
The Sequelae of Hematopoietic Stem Cell Transplantation in Adolescent and Young Adults: Protocol for A Systematic Review
Background Hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for Adolescent and Young Adults (age 15–39) with hematologic malignancy. Given the significant developmental milestones usually achieved during this unique life stage, this population is especially vulnerable to the interruption caused by a cancer diagnosis and its treatment. HSCT is a particularly invasive form of cancer therapy with many negative physical, social, and psychological sequelae. The long-term impact of HSCT in Adolescent and Young Adults with hematologic malignancies warrants a systematic investigation of its effects to best shape clinical care and health policy. Methods This protocol for a systematic review will focus on the long-term physical, psychological, social, spiritual, and health behavior effects experienced by Adolescents and Young Adults who undergo HSCT for hematologic malignancy. We have constructed a specific search strategy that queries these 5 domains, which will be applied to five databases – Embase, Pubmed, Cochrane Trials and Reviews, PsychInfo, and CINAHL – to identify key literature. Two independent reviewers will perform a title/abstract screen followed by full-text screen using standard screening templates to ensure inclusion of outcomes in the post-acute HSCT period. Risk of bias will be assessed using the University of Adelaide Joanna Briggs Institute Collaboration Critical Appraisal Tools. Data from included studies will be abstracted on study characteristics, study setting, sample characteristics, and outcomes. Given broad scope of the research question, data synthesis will focus on qualitative methods in accordance with Institute of Medicine standards. Discussion While Adolescent and Young Adults undergoing Hematopoietic Stem Cell Transplantation for hematologic malignancy are understood to have a unique survivorship experience, the sequelae of this treatment approach in this population have not been previously aggregated. This systematic review intends to expand insight into the Adolescent and Young Adult experiences with HSCT in order to inform age-appropriate survivorship care and deliver this life-saving intervention with the best possible outcomes. Systematic Review Registration PROSPERO registration number: CRD42022361663.
- 11 September 2023
- Published by Springer Nature in Research Square
Open AccessThe Sequelae of Hematopoietic Stem Cell Transplantation in Adolescent and Young Adults: Protocol for A Systematic Review
Background Hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for Adolescent and Young Adults (age 15–39) with hematologic malignancy. Given the significant developmental milestones usually achieved during this unique life stage, this population is especially vulnerable to the interruption caused by a cancer diagnosis and its treatment. HSCT is a particularly invasive form of cancer therapy with many negative physical, social, and psychological sequelae. The long-term impact of HSCT in Adolescent and Young Adults with hematologic malignancies warrants a systematic investigation of its effects to best shape clinical care and health policy. Methods This protocol for a systematic review will focus on the long-term physical, psychological, social, spiritual, and health behavior effects experienced by Adolescents and Young Adults who undergo HSCT for hematologic malignancy. We have constructed a specific search strategy that queries these 5 domains, which will be applied to five databases – Embase, Pubmed, Cochrane Trials and Reviews, PsychInfo, and CINAHL – to identify key literature. Two independent reviewers will perform a title/abstract screen followed by full-text screen using standard screening templates to ensure inclusion of outcomes in the post-acute HSCT period. Risk of bias will be assessed using the University of Adelaide Joanna Briggs Institute Collaboration Critical Appraisal Tools. Data from included studies will be abstracted on study characteristics, study setting, sample characteristics, and outcomes. Given broad scope of the research question, data synthesis will focus on qualitative methods in accordance with Institute of Medicine standards. Discussion While Adolescent and Young Adults undergoing Hematopoietic Stem Cell Transplantation for hematologic malignancy are understood to have a unique survivorship experience, the sequelae of this treatment approach in this population have not been previously aggregated. This systematic review intends to expand insight into the Adolescent and Young Adult experiences with HSCT in order to inform age-appropriate survivorship care and deliver this life-saving intervention with the best possible outcomes. Systematic Review Registration PROSPERO registration number: CRD42022361663.